Penumbra, Inc. (NYSE:PEN) Receives $360.33 Consensus Target Price from Analysts

Penumbra, Inc. (NYSE:PEN) has earned an average recommendation of “Hold” from the eighteen analysts that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $360.3333.

A number of analysts have recently commented on PEN shares. Royal Bank Of Canada reissued a “sector perform” rating and issued a $374.00 price objective on shares of Penumbra in a research report on Thursday, June 11th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings reiterated a “hold (c)” rating on shares of Penumbra in a research note on Friday, July 17th. Evercore reissued an “outperform” rating and set a $320.00 price target on shares of Penumbra in a research report on Monday, July 6th. Finally, Zacks Research cut Penumbra from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th.

Penumbra Stock Up 0.2%

Shares of Penumbra stock opened at $320.00 on Friday. The business’s 50 day simple moving average is $319.19 and its 200 day simple moving average is $330.07. Penumbra has a 52-week low of $221.26 and a 52-week high of $362.41. The firm has a market cap of $12.59 billion, a PE ratio of 73.73, a P/E/G ratio of 1.98 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.95 and a current ratio of 6.02.

Penumbra (NYSE:PEN) last released its earnings results on Wednesday, May 6th. The company reported $0.82 EPS for the quarter, missing the consensus estimate of $1.06 by ($0.24). The firm had revenue of $374.76 million during the quarter, compared to the consensus estimate of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company’s revenue was up 15.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.83 EPS. On average, analysts predict that Penumbra will post 5.02 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of PEN. Larson Financial Group LLC increased its position in shares of Penumbra by 4,100.0% during the 4th quarter. Larson Financial Group LLC now owns 84 shares of the company’s stock worth $26,000 after purchasing an additional 82 shares during the last quarter. CIBC Private Wealth Group LLC boosted its holdings in shares of Penumbra by 2,700.0% in the 4th quarter. CIBC Private Wealth Group LLC now owns 84 shares of the company’s stock valued at $26,000 after buying an additional 81 shares during the last quarter. Motiv8 Investments LLC acquired a new stake in shares of Penumbra in the 4th quarter valued at approximately $27,000. Morse Asset Management Inc bought a new position in shares of Penumbra in the fourth quarter valued at $39,000. Finally, Farther Finance Advisors LLC grew its stake in shares of Penumbra by 27.1% in the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after buying an additional 38 shares in the last quarter. 88.88% of the stock is owned by institutional investors and hedge funds.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.